Levamisolum [INN-Latin] en es it fr

Levamisolum [INN-Latin] Brand names, Levamisolum [INN-Latin] Analogs

Levamisolum [INN-Latin] Brand Names Mixture

  • No information avaliable

Levamisolum [INN-Latin] Chemical_Formula


Levamisolum [INN-Latin] RX_link


Levamisolum [INN-Latin] fda sheet

Levamisolum_[INN-Latin] FDA

Levamisolum [INN-Latin] msds (material safety sheet)

Levamisolum_[INN-Latin] MSDS

Levamisolum [INN-Latin] Synthesis Reference

No information avaliable

Levamisolum [INN-Latin] Molecular Weight

337.346 g/mol

Levamisolum [INN-Latin] Melting Point

No information avaliable

Levamisolum [INN-Latin] H2O Solubility

3 mg/mL

Levamisolum [INN-Latin] State


Levamisolum [INN-Latin] LogP


Levamisolum [INN-Latin] Dosage Forms

Solution; Tablets

Levamisolum [INN-Latin] Indication

For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.

Levamisolum [INN-Latin] Pharmacology

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.

Levamisolum [INN-Latin] Absorption

Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

Levamisolum [INN-Latin] side effects and Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

Levamisolum [INN-Latin] Patient Information

Levamisolum [INN-Latin] Organisms Affected

Gram negative and gram positive bacteria